01-11-2019 06:26 PM CET - Health & Medicine
Print

2017-2024 Industry Insights on Pet Cancer Therapeutics Market with Key Players: Zoetis Inc., Merial, Aratana Therapeutics Inc.

Press release from: Global Market Insights Inc.
Pet Cancer Therapeutics Market
Pet Cancer Therapeutics Market


The Pet Cancer Therapeutics Market valued above USD 140 million in 2016 and is projected to witness more than 10% CAGR from 2017 to 2024.

Increasing trend of pet adoption such as dogs and cats owing to improved economic status of people will drive pet cancer therapeutics market size. Furthermore, rising prevalence of pet cancer and growing pet healthcare expenditure will stimulate industry growth. Growing R&D initiatives to treat pet cancer will result into launch of novel products in the market over the forecast years. Industry players with robust product pipelines will continue to expand the market share with their innovative treatments.

Request for a sample of this research report @ www.gminsights.com/request-sample/detail/2017

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
• Zoetis Inc.
• Merial
• Aratana Therapeutics Inc.
• AB Science
• Regeneus Ltd
• Oasmia Pharmaceutical AB
• VetDC, Inc.
• CanFel Therapeutics

Lymphoma is the most common pet cancer type, especially in dogs. However, until the year 2016, there had been hardly any medicine available for dog cancer treatment. Many companies have robust drugs pipeline for lymphoma treatment which is anticipated to boost industry growth over the forecast years.

Mast cell cancer held largest pet cancer therapeutics market share, owing to availability of drugs for its treatment. However, shifting focus of companies from mast cell cancer to other cancer treatments may slower down the mast cell cancer therapeutics market growth over the forecast timeframe.

Chemotherapy drugs held the highest pet cancer therapeutics market share in 2016. Launch of new drugs for treatment of various cancers is anticipated to augment pet cancer therapeutics market share over the forecast years. Pet cancer vaccines are comparatively newer and lesser practiced medicine than chemotherapy; therefore, holds a relatively small market share. With more number of vaccines in pipeline the pet cancer therapeutics market share should at healthy CAGR over the forecast years.

Make an inquiry for purchasing this report @ www.gminsights.com/inquiry-before-buying/2017

North America pet cancer therapeutics market accounted for more than 80% of the overall revenue share in 2016, owing to the regional presence of several established players. Early product adoption and advances in product development to address different pet cancers will drive industry growth.
UK pet cancer therapeutics market held largest regional share in 2016. Pet cancer vaccines were available in most of the European regions before chemotherapy drugs. Vaccines market is likely to witness strong growth owing to introduction of new vaccines over the forecast period.

Pet Cancer Therapeutics Market By Medicine Type
• Chemotherapy drugs
• Vaccines
Pet Cancer Therapeutics Market By Species
• Dogs
• Cats
Pet Cancer Therapeutics Market By Cancer Type
• Lymphoma
• Mast cell cancer
• Melanoma
• Mammary and Squamous cell cancer

Global Market Insights Inc. is a global market research and management consulting company catering to leading corporations, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

Global Market Insights, Inc.
4 North Main Street
Selbyville, Delaware 19975 USA
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:sales@gminsights.com

This release was published on openPR.
News-ID: 1491910 • Views: 140
More releasesMore releases

You can edit or delete your press release here: